News

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.
United States Diabetes Drugs Market United States diabetes drugs market is expanding, driven by rising prevalence, biosimilar launches, sma ...